RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
1.250
-0.080 (-6.02%)
Nov 2, 2026, 2:59 PM EST - Market open
RenovoRx Employees
RenovoRx had 17 employees as of December 31, 2025. The number of employees increased by 7 or 70.00% compared to the previous year. That makes RenovoRx the 38,924th largest employer in the world and 5,663rd in the United States.
Employees
17
Change (1Y)
7
Growth (1Y)
70.00%
Revenue / Employee
$116,235
Profits / Employee
-$722,647
Market Cap
56.41M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | 7 | 70.00% |
| Dec 31, 2024 | 10 | 2 | 25.00% |
| Mar 31, 2024 | 10 | 0 | - |
| Dec 31, 2023 | 8 | -1 | -11.11% |
| Sep 30, 2023 | 10 | 0 | - |
| Jun 30, 2023 | 10 | 0 | - |
| Mar 31, 2023 | 10 | 0 | - |
| Dec 31, 2022 | 9 | 3 | 50.00% |
| Sep 30, 2022 | 10 | 0 | - |
| Jun 30, 2022 | 10 | 2 | 25.00% |
| Mar 31, 2022 | 10 | 4 | 66.67% |
| Dec 31, 2021 | 6 | -3 | -33.33% |
| Sep 30, 2021 | 10 | 1 | 11.11% |
| Jun 30, 2021 | 8 | - | - |
| Mar 31, 2021 | 6 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Inovio Pharmaceuticals | 112 |
| XBiotech | 87 |
| Clene | 79 |
| Fortress Biotech | 78 |
| Verrica Pharmaceuticals | 76 |
| Boundless Bio | 28 |
| Spero Therapeutics | 25 |
RNXT News
- 5 days ago - RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum - GlobeNewsWire
- 11 days ago - RenovoRx to Report Third Quarter 2026 Financial Results and Business Highlights on November 5, 2026 - GlobeNewsWire
- 26 days ago - RenovoRx enrolls first patient in PRISM-TAMP trial - TheFly
- 26 days ago - RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial - GlobeNewsWire
- 4 weeks ago - RenovoRx announces publication on TAMP platform’s potential - TheFly
- 4 weeks ago - RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 7 weeks ago - RenovoRx Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 7 weeks ago - RenovoRx Slides: Investor presentation - Filings